Startup profile · funding coverage
Monogram Health funding, valuation and investors
Value-based in-home kidney and polychronic care delivery plus benefit management for health plans.
Verified company research · funding, investors and latest developments
Keep track of Monogram Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Growth
$375M · January 2023
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$535M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Nashville, TN
Investors in latest funding
Other: TPG Capital , Frist Cressey Ventures , CVS Health , Cigna Ventures , Humana , Norwest Venture Partners
Overview
Monogram Health is a Nashville value-based specialty provider of in-home evidence-based care and benefit management for patients with polychronic conditions, including chronic kidney disease and ESRD. Founded/incubated with Frist Cressey Ventures in 2019 (Bill Frist chairs the board).
Closed $160M Series B led by TPG (2021) and $375M growth capital (Jan 2023) including CVS Health, Cigna Ventures, Humana, Memorial Hermann, SCAN, TPG, Frist Cressey, Heritage Group, Norwest, and others. Operates value-based partnerships across dozens of states.
Why Monogram Health is interesting
Nashville kidney-care scale-up incubated by Frist Cressey Ventures: $375M growth raise (Jan 2023) with CVS, Cigna, Humana, TPG — proof of Middle Tennessee health-services venture density.
Product & use cases
Combines in-home clinical care teams with tech-enabled disease/case management, utilization management, and medication therapy management under value-based contracts with plans and risk-bearing providers.
- Medicare Advantage and commercial plans managing CKD/ESRD cost and outcomes
- Slowing kidney disease progression and improving home-based care access
- Polychronic patients needing coordinated specialty + primary care in-home
Key facts
- Growth (Jan 2023): $375M with CVS, Cigna Ventures, Humana, TPG, Frist Cressey, Norwest, others
- Series B (Jun 2021): $160M led by TPG; FCV and Norwest participated
- Incubated/founded with Frist Cressey Ventures (2019); Bill Frist board chair
- In-home nephrology + polychronic care model across 30+ states (company materials)
Funding history (newest first)
Growth
2023-01 $375M- TPG Capital (participant)
- Frist Cressey Ventures (participant)
- CVS Health (participant)
- Cigna Ventures (participant)
- Humana (participant)
- Norwest Venture Partners (participant)
Source: Read source · monogramhealth.com
Series B
2021-06 $160M- TPG Capital (lead)
- Frist Cressey Ventures (participant)
- Norwest Venture Partners (participant)
- Humana (participant)
Source: Read source · monogramhealth.com
Related reading
Explore the analysis behind recent funding rounds and company developments.
Investors in our directory
Funds linked from Monogram Health's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Kidney-specialty VBC operator with plan partnerships and FCV healthcare network — not a pure SaaS navigation layer.
-
Somatus / Strive Health direct
Value-based kidney care competitors.
-
DaVita / Fresenius care models incumbent
Dialysis incumbents expanding upstream CKD programs.
-
Generic care management vendors adjacent
Utilization management without in-home nephrology delivery.
Notable stories
- FCV frames Monogram as a Nashville success story it incubated — growth capital funded national deployment of in-home kidney and polychronic care (fcventures.com).
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Monogram Health
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.